Preventing Dementia?
Critical Perspectives on a New Paradigm of Preparing for Old Age

Annette Leibing, PhD
Professor, medical anthropology
Université de Montréal
University researcher, CREGÉS
The brain: Use it or lose it!
Dementia prevention, the “new dementia”

“One Third of Dementia Cases May Be Preventable”


Prevention or risk reduction?
"Old" and "new" dementia

1. Early detection (MCI, prodromal phase)
2. Prevention
3. Brain is body (Leibing and Kampf 2013) in context
The “new dementia”: opening up the “cognitive paradigm”*

<table>
<thead>
<tr>
<th>‘Old’ dementia</th>
<th>‘New’ dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Focus on cognitive impairment*</td>
<td><strong>BPSD</strong> (Behavioral and Psychological Symptoms of dementia)</td>
</tr>
<tr>
<td>Early detection + early intervention, biomarkers, MCI (mild cognitive impairment)</td>
<td></td>
</tr>
<tr>
<td>Prevention = brain training (‘use it or lose it’)</td>
<td><strong>Prevention</strong>: Brain is body – esp. cardiovascular risk factors (see Lancet and others); The merging of vascular dementia and Alzheimer’s disease</td>
</tr>
<tr>
<td>Genetic explanation (1990 - )</td>
<td>“brain is body” (risk factors, microbiome...), genetics weaker explanation</td>
</tr>
</tbody>
</table>

* German Berrios (1987, 1989): 'Cognitive paradigm’ – “the view that an impairment of cognition (in practical terms, a memory deficit) is sufficient to define dementia.”
Situating the ‘new’ dementia

The “new” dementia = internationally circulating hopeful knowledge

Why the need to situate such knowledge?

Definition:

• Chandler and Munday (2011): situatedness is “[t]he dependence of meaning (and/or identity) on the specifics of particular sociohistorical, geographical, and cultural contexts, social and power relations, and philosophical and ideological frameworks, within which the multiple perspectives of social actors are dynamically constructed, negotiated, and contested.”

• Donna Haraway (1991): ‘situated knowledge’ – responsibility and accountability toward multiple existing (or possible) moral narratives
1. Situating prevention – epidemiological studies

The Lancet Global Health: Close to one in two cases of dementia could be preventable in low-to-middle-income countries (Mukadam et al. 2019)

In some (richer) regions of the world dementia incidence rates (some even speak of prevalence) are declining, for instance in the US (Manton, Gu and Ukraintseva 2005), Holland (Schrijvers et al. 2012), Sweden (Qiu et al. 2013), and England (Matthews et al. 2013), and others.

Explanation: Risk factors are better taken care of “The reasons for the decreased incidence are not clear, although several medical interventions that influence blood pressure, cholesterol, and inflammation may have contributed.” (Harvard TH Chan School of Public Health, 2020)

Question: national or privileged groups in countries with stark social inequalities?

Result: Should there be more public health campaigns (Control your diabetes, stop smoking...)?
Dutch PreDIVA study (Prevention of Dementia by Intensive Vascular Care)

• (preDIVA) is evaluating the effect of 6–8 years of nurse-led intensive vascular care on incident dementia in community-dwelling older people aged 70–78 years:
  • 4-monthly visits to a practice nurse who gave individually tailored lifestyle advice on smoking, diet, physical activity, weight and blood pressure (BP). If indicated, pharmacological treatment was started or optimised according to the prevailing guidelines on cardiovascular risk management.

• “Overall, no preventive effect of the intervention was found.”
  (van Middelaar et al. 2018)

• The intervention seemed more beneficial in a subgroup of individuals with untreated hypertension who adhered to the intervention.

• Explanation: People in Holland have an excellent access to health, social and education system: “a major impact might have been noticeable in the context of a country with a less efficient health care system” (Fagan 2016).
Conclusion 1:

• Dementia prevention is a deeply social, political and economic issue. If good access to a well-functioning health care system is so important, individualizing public health campaigns will probably have a limited effect.

• Strighini et al. (2017: 2): “socioeconomic adversity should be included as a modifiable risk factor in local and global health strategies, policies, and health-risk surveillance.”
2. Situating knowledge translation

Internationally circulating knowledge and local translations?
### National contexts, cont: Larger trials US vs. EU, cont.

<table>
<thead>
<tr>
<th>USA</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A4 trial</strong> (Anti-Amyloid Treatment in Asymptomatic Alzheimer’s)</td>
<td><strong>FINGER</strong> (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability)</td>
</tr>
<tr>
<td>One drug</td>
<td>Lifestyle/cardio-vascular</td>
</tr>
<tr>
<td>... whether an anti-amyloid antibody can slow memory loss caused by Alzheimer’s disease..</td>
<td>A 2-year multidomain intervention including nutritional guidance, physical activity, cognitive training, increased social activity, and intensive monitoring and management of metabolic and vascular risk factors</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>USA</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autosomal Dominant Alzheimer’s Disease (ADAD) Trial</strong></td>
<td><strong>PREVENT Dementia study</strong></td>
</tr>
<tr>
<td>One drug</td>
<td>Lifestyle/cardio-vascular</td>
</tr>
<tr>
<td>This study focuses on whether two investigational drugs – an active immunotherapy (CAD106) and a BACE (beta-secretase 1) inhibitor (CNP520) – can prevent or delay the onset of Alzheimer’s symptoms.</td>
<td>UK study: research focuses on people in middle age to identify biological and psychological factors which may increase the risk of dementia in later life. Once identified, we would like to select those people at high risk and intervene in this process. These interventions might be lifestyle changes or measures to affect the risk of an individual developing dementia.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>USA</th>
<th>EUROPE</th>
<th>EUROPE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMERGE</strong>  (also in Europe)</td>
<td>To evaluate the efficacy and safety of Aducanumab (BIIB037) in subjects with early Alzheimer's disease (Phase 3). Also European countries, sponsored by US company (Biogen)</td>
<td><strong>PreDIVA (Prevention of dementia by intensive vascular care)</strong></td>
</tr>
<tr>
<td>One drug</td>
<td><strong>Cardiovascular risk factors/lifestyle</strong></td>
<td>A Dutch 6-year long multicenter RCT comparing standard and intensive care of cardiovascular risk factors in preventing dementia and disability in older people: a multi-component intensive vascular care addresses hypertension, hypercholesterolemia, smoking habits, excessive weight, physical inactivity, and diabetes mellitus, which are strictly controlled with medication and lifestyle interventions.</td>
</tr>
<tr>
<td><strong>TOMORROW Trial</strong></td>
<td>3,500 asymptomatic individuals, some of whom have the Alzheimer's risk gene (APOE-e4) or the TOMM40 risk gene. The trial will explore whether the anti-diabetes drug pioglitazone can prevent mild cognitive impairment due to Alzheimer's disease.</td>
<td><strong>MAPT (Multidomain Alzheimer Preventive Trial)</strong></td>
</tr>
<tr>
<td>One drug</td>
<td><strong>Cardiovascular risk factors/lifestyle</strong></td>
<td>A French 3-year multicenter RCT evaluating the efficacy of isolated supplementation with ω-3 fatty acid, isolated multidomain intervention, or their combination in the prevention of cognitive decline in frail individuals who are at least 70 years old. Also group training sessions (physical exercise, cognitive training, and nutritional advice) and yearly personalized preventive consultations that aim to identify dementia and frailty risk factors (vascular risk factors, nutritional problems, sensory deficits, mood disorders, and walking difficulties).</td>
</tr>
</tbody>
</table>
US vs. EU

• The participants [from the US] receive solanezumab, an antibody-based drug that aims to reduce brain amyloid-beta, which recently failed to improve mild Alzheimer’s dementia. Despite the failure, researchers speculate the drug may be effective in preventing dementia in people who have amyloid-beta aggregates in the brain (Kegel 2017).

• Recent research suggests changes in the brain may precede symptoms of Alzheimer’s disease by many years. (...) Our research (...) focuses on people in middle age to identify biological and psychological factors which may increase the risk of dementia in later life. Once we have identified which factors are changing we would like to select those people at high risk and intervene in this process. These interventions might be lifestyle changes or measures to affect the risk of an individual developing dementia. (PREVENT n.d., UK)
Pharma-dominated major int’l prevention initiatives

• **The UK-based Dementia Discovery Fund**: “Our goal is to invest over $200m over fifteen years to support the creation of novel disease-modifying drugs for dementia... “The Department of Health, the charity Alzheimer’s Research UK and ... six pharmaceutical firms have raised $100m (£65m) to invest in early-stage, novel treatments for (...) dementia (...) [T]he company is joined by the US drugmakers Johnson & Johnson, Biogen, Eli Lilly and Pfizer, and Japan’s Takeda.”

• **The (US based) Global Alzheimer Platform**: “the GAP Foundation is joining together leading academic researchers, pharmaceutical companies, nonprofit organizations and foundations, and governments around the world to reduce the time, cost and risk of Alzheimer’s clinical trials, in order to speed innovative medicines ...”
Conclusion 2:

• Different countries might receive different kinds of recommendations.

• « MCI is given less importance in Europe when compared to the US. » (Peter Whitehouse, personal communication)

• And Canada?

• The influence of such translation processes (pharmaceutical industry lobbying, media restrictions etc.) need to be studied in more detail.
3. Dementia prevention in Brazil

Embedding risk factors in local contexts
Brazil – aging, dementia, risk factors

• 7.3% seniors in 1991; 15% in 2025
• Life expectancy: 75.67 (WHO 2018)

Older people and
Hypertension: The prevalence of arterial hypertension was 74.9% (Lima Sousa et al. 2019)
Diabetes: 10% in 1998, 13% in 2003 and 16% in 2008 // 17.9% (2011) (Mendes et al. 2011)

• 30% of Brazilians smoke 20+ cigarettes/day, national tobacco restriction programs reached less young women and older people (Monteiro et al. 2010)
• 40% prevalence of physical inactivity among adults, highly class dependent (Hallal et al. 2012)
• Depression (66-84 yrs): Prevalence rates of 7.0% for major depression, 26.0% for CSDS, and 3.3% for dysthymia (Barcelos-Ferreira et al. 2010)

• Probable increase in the prevalence of dementia in the 65+ age-group, from 7.6% to 7.9% between 2010 and 2020: 55,000 new cases per year (Burlá et al. 2013)
“Free medications, here at the Popular Pharmacy”
“Diabetes and hypertension, It is through this program that you get the meds with until 90% of discount. In the case of hypertension and diabetes, these meds are for free.”

“Não deveríamos ter tantos casos [de demência] por aqui; aqui os remédios para diabetes e hipertensão estão de graça. Mas a vida dessas pessoas é muito difícil...” (Cristina Hoffmann, MS, 2016)
Geriatricians about dementia prevention in Brazil

• ... there is the cultural question, that people think they only have to go to the doctor when they are very ill. And do not do anything before getting sick... And then, when they need help, the access to health care is very difficult, (Female geriatric resident)

• They don’t take these medications – hypertension is so common, why take this medication? Because it makes people ordinary. ... Hypertension is a disease of poor people. ‘I want to have a disease of rich people’, they say. (Male geriatrician)

• Vascular dementia in Brazil, ave Maria! I am sure it is worse than in any other country. In the first world, diabetes and hypertension are well controlled. We will never get there. That is very sad. And especially in the public system [SUS], that’s a mess. (...) It is difficult to have access to medications, difficult to change lifestyle, difficult to change the diet and all that. (...) The access to health care is difficult – because of all this patients have more ischemic events, microangiopathies (...) And so rates of mixed dementia and the vascular one are very high. In Ceilândia [very poor area], people are unable to buy certain medications. And if I decide to prescribe one they get for free, it will likely be an old medication, with heavy side effects. It is heart-breaking. Sometimes families can buy one medication, but not another. (female geriatrician)
Cintia Engel

• Studying obstacles in everyday life through immersive ethnographies at home.

• “Partilha e cuidado das demências: entre interações medicamentosas e rotinas”, 2020 (University of Brasilia).
Care of self
Conclusion

• The preventive turn in dementia research is a real chance for a better old age, when a) the complexity and interplay of genetic, physiological, lifestyle, environmental, and political-economic factors are taken into consideration and b) when, first of all, structural factors – access to good health care, food, and education, as well as a clean environment – are guaranteed for all.

• Translations of findings need to be carefully monitored, for example by looking at interest groups and (situated) differences between groups and nations at both macro and micro levels of “doing prevention”. *

• *NeuroNet ERA ELSA study in Canada, Switzerland and Germany (plus Brazil and eventually Israel)
• Neurologist Sir James Crichton-Browne (1905):

“Americans break down at an earlier age than Europeans, especially from nervous ailments, and he (Hamilton) attributes this to their struggles for the rapid accumulation of wealth, to the competition and ambition which are largely stimulated by agitational newspapers... to hustling, over-eating, insufficient exercise and luxurious living general.”
Thank you et Merci!

... for your attention.

For further questions: annette.leibing@umontreal.ca

This research is funded by a SSHRC Insight grant and by an ERA-NET NEURON - ELSA grant (Canadian part: FRQS and CIHR)